Posted by Michael Wonder on 06 Jun 2022
Novavax faces high stakes FDA review this week that will decide the fate of its COVID vaccine in the U.S.
6 June 2022 - If they endorse the vaccine, the FDA will almost certainly authorise the shot for adults in the U.S.
Novavax’s COVID-19 vaccine will face the scrutiny of the FDA’s independent immunisation experts this week, a crucial step on the path toward U.S. regulatory authorisation two years after the Maryland biotech company received taxpayer funding to develop the shots.
